HEADER UNKNOWN FUNCTION 15-MAR-06 2GD3 TITLE NMR STRUCTURE OF S14G-HUMANIN IN 30% TFE SOLUTION COMPND MOL_ID: 1; COMPND 2 MOLECULE: HUMANIN; COMPND 3 CHAIN: A; COMPND 4 ENGINEERED: YES; COMPND 5 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 OTHER_DETAILS: S14G-HUMANIN WAS PREPARED BY FMOC-SOLID PHASE SOURCE 4 SYNTHESIS ON O-CL-TRITYL-AMIDOMETHYL POLYSTYRENE RESIN (EVANGELOU, SOURCE 5 A., ZIKOS, C., LIVANIOU, E., EVANGELATOS, G.P. "HIGHYIELD, SOLID- SOURCE 6 PHASE SYNTHESIS OF HUMANIN, AN ALZHEIMER'S DISEASE ASSOCIATED, NOVEL SOURCE 7 24-MER PEPTIDE WHICH CONTAINS A DIFFICULT SEQUENCE" J. PEPTIDE SCI. SOURCE 8 2004, 10, 631 635). THE PEPTIDE WAS PURIFIED TO 95% WITH SEMI- SOURCE 9 PREPARATIVE RP-HPLC AND SUITABLY CHARACTERIZED. THE SEQUENCE IS SOURCE 10 NATURALLY FOUND IN HOMO SAPIENS (HUMAN). KEYWDS S14G-HUMANIN; HUMANIN; ALZHEIMER'S DISEASE; NEUROPROTECTION; NMR; CD, KEYWDS 2 UNKNOWN FUNCTION EXPDTA SOLUTION NMR NUMMDL 14 AUTHOR D.BENAKI,C.ZIKOS,A.EVANGELOU,E.LIVANIOU,M.VLASSI,E.MIKROS,M.PELECANOU REVDAT 5 29-MAY-24 2GD3 1 REMARK REVDAT 4 20-OCT-21 2GD3 1 REMARK SEQADV REVDAT 3 24-FEB-09 2GD3 1 VERSN REVDAT 2 03-OCT-06 2GD3 1 JRNL REVDAT 1 19-SEP-06 2GD3 0 JRNL AUTH D.BENAKI,C.ZIKOS,A.EVANGELOU,E.LIVANIOU,M.VLASSI,E.MIKROS, JRNL AUTH 2 M.PELECANOU JRNL TITL SOLUTION STRUCTURE OF SER14GLY-HUMANIN, A POTENT RESCUE JRNL TITL 2 FACTOR AGAINST NEURONAL CELL DEATH IN ALZHEIMER'S DISEASE. JRNL REF BIOCHEM.BIOPHYS.RES.COMMUN. V. 349 634 2006 JRNL REFN ISSN 0006-291X JRNL PMID 16945331 JRNL DOI 10.1016/J.BBRC.2006.08.087 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH D.BENAKI,C.ZIKOS,A.EVANGELOU,E.LIVANIOU,M.VLASSI,E.MIKROS, REMARK 1 AUTH 2 M.PELECANOU REMARK 1 TITL SOLUTION STRUCTURE OF HUMANIN, A PEPTIDE AGAINST ALZHEIMER'S REMARK 1 TITL 2 DISEASE-RELATED NEUROTOXICITY. REMARK 1 REF BIOCHEM.BIOPHYS.RES.COMMUN. V. 329 152 2005 REMARK 1 REFN ISSN 0006-291X REMARK 1 PMID 15721287 REMARK 1 DOI 10.1016/J.BBRC.2005.01.100 REMARK 1 REFERENCE 2 REMARK 1 AUTH Y.HASHIMOTO,T.NIIKURA,H.TAJIMA,T.YASUKAWA,H.SUDO,Y.ITO, REMARK 1 AUTH 2 Y.KITA,M.KAWASUMI,K.KOUYAMA,M.DOYU,G.SOBUE,T.KOIDE,S.TSUJI, REMARK 1 AUTH 3 J.LANG,K.KUROKAWA,I.NISHIMOTO REMARK 1 TITL A RESCUE FACTOR ABOLISHING NEURONAL CELL DEATH BY A WIDE REMARK 1 TITL 2 SPECTRUM OF FAMILIAL ALZHEIMER'S DISEASE GENES AND ABETA. REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 98 6336 2001 REMARK 1 REFN ISSN 0027-8424 REMARK 1 PMID 11371646 REMARK 1 DOI 10.1073/PNAS.101133498 REMARK 1 REFERENCE 3 REMARK 1 AUTH Y.HASHIMOTO,Y.ITO,T.NIIKURA,Z.SHAO,M.HATA,F.OYAMA, REMARK 1 AUTH 2 I.NISHIMOTO REMARK 1 TITL MECHANISMS OF NEUROPROTECTION BY A NOVEL RESCUE FACTOR REMARK 1 TITL 2 HUMANIN FROM SWEDISH MUTANT AMYLOID PRECURSOR PROTEIN REMARK 1 REF BIOCHEM.BIOPHYS.RES.COMMUN. V. 283 460 2001 REMARK 1 REFN ISSN 0006-291X REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : XWINNMR 2.6, CNS 1.1 REMARK 3 AUTHORS : BRUKER (XWINNMR), BRUNGER, A.T. (CNS) REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: STARTING FROM AN EXTENDED STRUCTURE A REMARK 3 TOTAL OF 300 STRUCTURES WERE GENERATED FROM 133 NOE-DERIVED REMARK 3 DISTANCE RESTRAINTS AND 2 DISTANCE RESTRAINTS BASED ON REMARK 3 TEMPERATURE COEFFICIENT DATA USING THE SIMULATED ANNEALING AND REMARK 3 ENERGY MINIMIZATION PROTOCOL IN THE PROGRAM CNS, VERSION 1.1 REMARK 4 REMARK 4 2GD3 COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 23-MAR-06. REMARK 100 THE DEPOSITION ID IS D_1000036971. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 298; 280 REMARK 210 PH : 2.7; 2.7 REMARK 210 IONIC STRENGTH : 60 MICROM NAN3; 60 MICROM NAN3 REMARK 210 PRESSURE : AMBIENT; AMBIENT REMARK 210 SAMPLE CONTENTS : 1.3 MM S14G-HUMANIN; 60 MICROM REMARK 210 NAN3 TO PREVENT MICROBIAL GROWTH; REMARK 210 H2O/TFE-D3 7:3; PH 2.6 REMARK 210 (UNCORRECTED FOR THE PRESENCE OF REMARK 210 TFE); AT 298 AND 280 K REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D NOESY; 2D TOCSY REMARK 210 SPECTROMETER FIELD STRENGTH : 500 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : XWINNMR 2.6, SPARKY 3, CNS 1.1 REMARK 210 METHOD USED : SIMULATED ANNEALING TORSION REMARK 210 ANGLE DYNAMICS REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 300 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 14 REMARK 210 CONFORMERS, SELECTION CRITERIA : 14 CONVERGENT CONFORMERS ARE REMARK 210 PRESENTED HAVING THE LOWEST REMARK 210 ENERGY AND THE BEST STRUCTURAL REMARK 210 QUALITY IN RAMACHADRAN PLOT REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: THIS STRUCTURE WAS DETERMINED USING STANDARD 2D REMARK 210 HOMONUCLEAR TECHNIQUES REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 PRO A 3 -166.98 -70.62 REMARK 500 1 GLU A 15 -67.63 -132.94 REMARK 500 1 ILE A 16 31.23 -99.13 REMARK 500 2 ALA A 2 90.17 -175.80 REMARK 500 2 PRO A 3 -168.08 -70.96 REMARK 500 2 LEU A 18 83.23 -150.72 REMARK 500 3 LYS A 21 -47.10 -135.26 REMARK 500 3 ARG A 23 36.03 -99.47 REMARK 500 4 ASP A 17 42.13 -96.63 REMARK 500 5 ASP A 17 38.79 -142.49 REMARK 500 5 LEU A 18 77.87 -119.11 REMARK 500 5 ARG A 22 88.91 -60.40 REMARK 500 6 THR A 13 49.31 -90.39 REMARK 500 6 LYS A 21 -167.10 -123.80 REMARK 500 7 PRO A 3 -167.91 -70.76 REMARK 500 7 ARG A 4 -80.02 -119.07 REMARK 500 7 ILE A 16 45.19 -92.91 REMARK 500 7 VAL A 20 31.00 -98.13 REMARK 500 7 ARG A 23 -46.11 -130.59 REMARK 500 8 ALA A 2 108.27 -175.29 REMARK 500 8 PRO A 3 -164.09 -65.15 REMARK 500 8 ARG A 4 -71.51 -59.80 REMARK 500 8 GLU A 15 -46.23 -130.36 REMARK 500 8 VAL A 20 31.48 -98.63 REMARK 500 9 ILE A 16 44.17 -95.11 REMARK 500 9 LEU A 18 77.99 -150.41 REMARK 500 9 VAL A 20 82.79 -157.26 REMARK 500 10 ASP A 17 43.84 -95.47 REMARK 500 10 LEU A 18 77.98 -109.12 REMARK 500 10 LYS A 21 91.32 -67.15 REMARK 500 11 ALA A 2 79.66 -151.86 REMARK 500 11 PRO A 3 -164.06 -66.09 REMARK 500 11 ARG A 4 -74.36 -59.93 REMARK 500 11 THR A 13 -72.10 -60.95 REMARK 500 11 ARG A 22 31.42 -150.76 REMARK 500 12 PRO A 3 -166.12 -69.78 REMARK 500 12 PRO A 19 83.94 -68.51 REMARK 500 13 PRO A 3 -168.24 -71.29 REMARK 500 13 ARG A 4 -67.07 -127.92 REMARK 500 14 PRO A 3 -167.70 -71.08 REMARK 500 14 LEU A 18 82.51 -160.06 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1Y32 RELATED DB: PDB REMARK 900 THE SOLUTION STRUCTURE IN 30% TFE OF THE PARENT PEPTIDE, HUMANIN, REMARK 900 WHICH HAS A SER IN THE PLACE OF GLY14 DBREF 2GD3 A 1 24 UNP Q8IVG9 HUNIN_HUMAN 1 24 SEQADV 2GD3 GLY A 14 UNP Q8IVG9 SER 14 ENGINEERED MUTATION SEQRES 1 A 24 MET ALA PRO ARG GLY PHE SER CYS LEU LEU LEU LEU THR SEQRES 2 A 24 GLY GLU ILE ASP LEU PRO VAL LYS ARG ARG ALA HELIX 1 1 PRO A 3 GLY A 14 1 12 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MODEL 1